Haleon plc (LON:HLN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 32.00B -3.0% |
| Revenue (ttm) | 11.15B +1.2% |
| Net Income | 1.62B +6.6% |
| EPS | 0.18 +8.5% |
| Shares Out | 8.81B |
| PE Ratio | 20.06 |
| Forward PE | 16.64 |
| Dividend | 0.07 (2.01%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 25,425,384 |
| Open | 369.70 |
| Previous Close | 368.60 |
| Day's Range | 362.70 - 371.30 |
| 52-Week Range | 274.40 - 416.10 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 416.59 (+14.67%) |
| Earnings Date | Jul 30, 2026 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal dr... [Read more]
Full Company ProfileFinancial Performance
In 2025, Haleon's revenue was 11.03 billion, a decrease of -1.81% compared to the previous year's 11.23 billion. Earnings were 1.67 billion, an increase of 15.60%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for HLN stock is "Buy." The 12-month stock price target is 417p, which is an increase of 14.67% from the latest price.
News
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Haleon H1 Earnings Call Highlights
Haleon NYSE: HLN said its second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, supported by improved execution in North America, continued growth in emerging markets...
Supplier Of Advil, Haleon Reports Half-Year 2026 Results
(RTTNews) - Haleon plc (HLN.L), a consumer health company known for brands such as Advil, Sensodyne, Centrum, Panadol, and Voltaren, announced its unaudited financial results for the six months ended ...
Haleon Earnings Call Transcript: H1 2026
Q2 organic sales grew 3.1% with margin and EPS improvements, led by North America, China, and Latin America. Outlook remains confident for 3%-5% full-year growth, with H2 expected to benefit from emerging markets, cold and flu recovery, and continued innovation.
Haleon Quarterly report: H1 2026
Haleon has published its H1 2026 quarterly earnings report on July 30, 2026.
Haleon Slides: H1 2026
Haleon has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
Haleon posts in-line quarterly sales growth as oral health, North America drive demand
British consumer health company Haleon posted second-quarter organic sales growth of 3.1% on Thursday, in line with estimates, driven by strong demand for its oral health products and accelerating gro...
Haleon files automatic mixed securities shelf
16:08 EDT Haleon (HLN) files automatic mixed securities shelf
Haleon PLC (LSE:HLN) Q2 2026 Earnings Report Preview: What to Look For
Haleon PLC (LSE:HLN) Q2 2026 Earnings Report Preview: What to Look For
A Look at Haleon PLC (HLN) After 3.3% Gain -- GF Value $9.77 vs Price $10.27
A Look at Haleon PLC (HLN) After 3.3% Gain -- GF Value $9.77 vs Price $10.27
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...
From shampoo to cookies, consumer products get an AI makeover
French cosmetics company L'Oreal has used AI to identify molecules in its skincare products that can be repurposed for use in shampoo and can now create products four times faster than before, a seni...
Microsoft (MSFT) Partners with Haleon to Expand AI Solutions Amid Workforce Cuts
Microsoft (MSFT) Partners with Haleon to Expand AI Solutions Amid Workforce Cuts
“Better Everyday Health to Consumers Globally”: Microsoft Stock (NASDAQ:MSFT) Jumps With Haleon Team-Up
Tech giant Microsoft ($MSFT) has had a lot of luck with artificial intelligence (AI) in healthcare-related use cases lately. And it just landed one more after teaming up with Haleon…
Microsoft Stock (MSFT) Jumps 3% as Haleon (HLN) Deepens 5-Year AI Partnership
Shares of U.S. software company Microsoft ($MSFT) surged on Wednesday after consumer health firm Haleon ($HLN) announced a new five-year deal with the tech giant. The deal will expand Haleon’s…
Haleon (HLN) Partners with Microsoft to Enhance AI and Digital Technologies
Haleon (HLN) Partners with Microsoft to Enhance AI and Digital Technologies
Haleon Forms Five-Year Partnership with Microsoft to Enhance AI Technologies (HLN)
Haleon Forms Five-Year Partnership with Microsoft to Enhance AI Technologies (HLN)
Haleon (HLN) Partners with Microsoft for Enhanced Digital Solutions
Haleon (HLN) Partners with Microsoft for Enhanced Digital Solutions
Haleon announces new five-year collaboration with Microsoft
Haleon (HLN) announces a new five-year collaboration with Microsoft (MSFT) to scale digital, data and AI capabilities across the business. The new agreement builds on Haleon’s existing use of Microsof...
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
LONDON--(BUSINESS WIRE)-- #AI--Haleon, a consumer health company solely focused on better everyday health, today announces a new five-year collaboration with Microsoft to scale digital, data and AI ca...
Haleon price target lowered to 315 GBp from 335 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Haleon (HLN) to 315 GBp from 335 GBp and keeps an Underweight rating on the shares.
Haleon downgraded to Neutral from Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Edward Lewis downgraded Haleon (HLN) to Neutral from Buy with a 365 GBp price target
Haleon price target lowered to 430 GBp from 440 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Haleon (HLN) to 430 GBp from 440 GBp and keeps an Overweight rating on the shares.
Haleon introduces new corporate identity in Nigeria, partners with Fidson
Haleon’s collaboration with Fidson Healthcare forms part of this approach, reinforcing the value of local production in supporting trusted everyday health brands in Nigeria. The post Haleon introduces...
Haleon to invest ₹2,000 crore in first India manufacturing facility
Global consumer healthcare company Haleon has announced plans to invest approximately ₹2,000 crore (£175 million) to establish its first manufacturing facility in India, marking a major expansion of i...